Shanghai RAAS Blood Products announced that the company intends to acquire 100% equity of Nanyue Pharmaceutical Co., Ltd. through cash payment, where 87.9766% of the equity transfer consideration is 3.695 billion yuan, and 12.0234% of the equity transfer consideration is 0.505 billion yuan, totaling 4.2 billion yuan. After this Trade is completed, Nanyue Bio will become a wholly-owned subsidiary of Shanghai RAAS. Additionally, if Nanyue Bio's plasma collection volume reaches 305 tons in 2025, Shanghai RAAS will pay an additional 50 million yuan or have consideration.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
The "reciprocal tariffs" imposed by Trump have taken effect! U.S. stock index futures have collectively plunged, the fear index has surged, how do the Institutions interpret this?
The specific tariff rates imposed by the USA on multiple countries have been announced, with a reciprocal tariff of 20% for the European Union and 24% for Japan.
Futu Morning Report | Trump's reciprocal tariffs cause a significant drop in risk Assets, Nasdaq Futures down over 4%; Trump's first 50 days see poor performance in U.S. stocks, creating one of the worst records for a U.S. president in 75 years.
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
上海莱士:拟以42亿元收购南岳生物100%股权
Shanghai RAAS Blood Products plans to acquire 100% equity of Nanyue Bio for 4.2 billion yuan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 329
Write a comment
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report